Inimmune’s focus is to discover and develop disease-modifying immunotherapies. Currently, our pipeline includes two clinical-stage Toll-like receptor (TLR) agonists in immuno-oncology and allergy. Both of these TLR agonists generated disease-modifying therapeutic responses in pre-clinical models. Late-stage pre-clinical programs are focused on developing innate immune agonists as next-generation vaccine adjuvants and discovery-stage projects are centered around novel, non-TLR innate immune agonists and antagonists.
Inimmune was founded in early 2016 by Drs. Jay Evans, David Burkhart, Helene Bazin-Lee, Kendal Ryter, and a team of 11 highly trained scientists. This team of chemists, immunologists, and formulation scientists have been at the cutting edge of innovation for over 10 years as former GSK Vaccines scientists and investigators. They now are working to create new immunotherapies directed at making meaningful and lasting clinical impacts in the areas of allergy, autoimmunity, infectious disease, and cancer. Through its technology, assets, expertise, and favorable IP positioning, Inimmune is poised to stand up and become a leader in these clinical areas.
We believe in making meaningful and lasting positive clinical impacts for the betterment of humankind. Our team has over 20 years of expertise in discovering and developing safe and effective immunomodulators that can be used to treat a wide variety of diseases and disorders. We have a proven track record of innovation, intellectual property generation, effective collaboration, and sourcing external funding to drive our immune therapies forward.
